Apr
4
Winstrol, Successful Treatment For Primary Refractory Anemia
April 4, 2006 |
Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen.
Department of Clinical Hematology, Affiliated No. 2 Hospital, Xi’an Jiaotong University, 157 West Five Road, Xi’an 710004, PR China; Environments and Genes Related to Diseases Key Laboratory of the Education Ministry, Xi’an Jiaotong University, Xi’an 710061, PR China.
We investigated the efficacy and safety of a combination regimen in 63 patients with primary refractory anemia (RA). The daily treatment protocol comprised all-trans retinoic acid (ATRA) (30mg/m(2)), calcitriol (0.1mug/m(2)), and androgen (stanozolol 3mg/m(2), or danazol 300mg/m(2)) in three separate doses for eight consecutive weeks. Hematologic improvement was observed in 43 (68.3%) patients. The treatment administered was generally well tolerated, with no severe regimen-related toxicity. The overall survival rates at 3 and 5 years were 68.72% and 53.18%, respectively. These results indicate that this combination regimen is an effective and well-tolerated treatment for patients with RA.
As you can see, every day we discovered new applications and uses of stanozolol, winstrol
RSS feed










